TABLE 2.
Subgroup analyses of 24h-UTP based on treatment duration, baseline of 24h-UTP, baseline of Scr and type of RASI.
| Criteria for grouping | Subgroups | n | MD (95%CI) | I2(%) | Z | P |
|---|---|---|---|---|---|---|
| Treatment duration | 8 weeks | 10 | −382.24(−601.85, −162.64) | 98 | 3.41 | 0.0006 |
| 12 weeks | 4 | −270.86(−457.87, −83.85) | 96 | 2.84 | 0.005 | |
| ≥16 weeks | 3 | −782.68(−1935.53, 370.17) | 99 | 1.33 | 0.18 | |
| Baseline of 24h-UTP | <1 g | 3 | −65.29(−101.21, −29.37) | 53 | 3.56 | 0.0004 |
| 1–2 g | 7 | −271.02(−303.06, −238.97) | 0 | 16.58 | <0.00001 | |
| >2 g | 7 | −773.06(−1140.44, −405.67) | 98 | 4.12 | <0.0001 | |
| Baseline of Scr | <90 μmol/L | 6 | −568.39(−1019.54, −117.25) | 99 | 2.47 | 0.01 |
| 90–110 μmol/L | 4 | −200.80 (−352.74, −48.85) | 95 | 2.59 | 0.01 | |
| 110–133 μmol/L | 2 | −343.80(−629.04, −58.56) | 0 | 2.36 | 0.02 | |
| >133 μmol/L | 4 | −651.13(−1042.86, −259.40) | 95 | 3.26 | 0.001 | |
| Type of RASI | ACEI | 7 | −481.13(−740.83, −221.43) | 96 | 3.63 | 0.0003 |
| ARB | 10 | −412.05(−599.69, −224.41) | 99 | 4.30 | <0.0001 |
RASI, Renin-angiotensin-aldosterone system inhibitor; ACEI, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin-receptor blocker; 24h-UTP, 24h-urine total protein; Scr, Serum creatinine.